Intellia Therapeutics, Inc. reported $60M of revenue over the trailing twelve months, +13% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $60M (to Q2 2026). Net income: −$400M, trailing twelve months to Q2 2026. Free cash flow: −$349M, trailing twelve months to Q2 2026. Operating margin: −845%, trailing twelve months to Q2 2026.

NTLAIntellia Therapeutics, Inc.

Healthcare

$13.08-16% 1Y

$13.08

$8.0452 weeks$27.98

Latest close: back above its 200-day averageOct 9, 2026what changed →

NTLA as reported

Intellia Therapeutics, Inc. reported $60M of revenue over the trailing twelve months, +13% on the year before. 9 reported series are charted on this page, each one as filed.

$60M

Revenue, trailing twelve months · to Q2 2026 · +13% against the twelve months before

Net income: −$400M
Net income · −17% year on year · trailing twelve months to Q2 2026
Free cash flow: −$349M
Free cash flow · −17% year on year · trailing twelve months to Q2 2026
Operating margin: −845%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for NTLA, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$60M	+13%	Q2 2026
Net income	−$400M	−17%	Q2 2026
EPS	−$3.35	−28%	Q2 2026
Gross margin	100%	n/a	Q4 2019 · 26 quarters behind
Operating margin	−845%	n/a	Q2 2026
Net margin	−796%	n/a	Q2 2026
ROE	−60%	n/a	Q2 2026
ROA	−49%	n/a	Q2 2026
Free cash flow	−$349M	−17%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.